Urologix
This article was originally published in The Gray Sheet
Executive Summary
Expanded labeling approval for the Targis system includes a claim for treatment of the obstruction in the urethra caused by benign prostatic hyperplasia, the firm reports Aug. 7. No similar devices have been approved for this indication, the firm states. The system is currently approved for treatment BPH symptoms, such as frequent urination. Separately, the company reports revenues of $11.2 mil. for fiscal year 1998 ending June 30 compared to $5.5 mil. one year ago. Urologix books a larger net loss in FY 1998 ($15 mil.) versus its net loss in the year prior period ($8.2 mil.)